MYRIAD GENETICS INC.

Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing

11 Jul 2024 09:00:00 By Nasdaq GlobeNewswire

Myriad Genetics Announces Second Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

09 Jul 2024 09:00:00 By Nasdaq GlobeNewswire

Myriad Genetics Earns 2024 Great Place To Work® Certification™

02 Jul 2024 09:00:00 By Nasdaq GlobeNewswire

Survey Suggests Increased Attention on Mental Health Warranted in the Run-Up to the Election

24 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Collaborates with GSK to Improve Access to HRD Testing in 9 Countries

11 Jun 2024 08:00:00 By Nasdaq GlobeNewswire

Myriad Genetics Launches New Universal Plus Panel for Foresight® Carrier Screen

04 Jun 2024 09:00:00 By Nasdaq GlobeNewswire

Genetics in Medicine Publishes Myriad Genetics Patient-Outcomes Study Validating RiskScore® as a Clinical Breast Cancer Risk Assessment Tool

03 Jun 2024 16:05:00 By Nasdaq GlobeNewswire

QIAGEN and Myriad Genetics develop distributable homologous recombination deficiency test for global research and companion diagnostics applications

30 May 2024 17:55:30 By Nasdaq GlobeNewswire

Myriad Genetics Showcases New Research and Product Innovations Advancing Cancer Care at 2024 ASCO® Annual Meeting

23 May 2024 18:00:00 By Nasdaq GlobeNewswire

New Study Published in JCO Precision Oncology Shows Myriad Genetics' Prolaris Test Can Predict Benefit of Hormone Therapy Treatment in Men with Localized Prostate Cancer

16 May 2024 16:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Reports Strong First Quarter 2024 Financial Results; Achieves 12% Revenue Growth Year-Over-Year; Significantly Improved Year-Over-Year Net Loss and Generated Positive Adjusted EBITDA

07 May 2024 16:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Announces Reorganization of European Operations and Sale of EndoPredict Business

07 May 2024 09:00:00 By Nasdaq GlobeNewswire

Myriad Genetics to Release First Quarter 2024 Financial Results on May 7, 2024

30 Apr 2024 16:05:00 By Nasdaq GlobeNewswire

Nearly Half of Americans Say They’ve Lost Time in Their Lives Due to Poor Mental Health, According to the GeneSight Mental Health Monitor

17 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

New Myriad Genetics Study Published in Prenatal Diagnosis Shows High Positive Predictive Value for 22q11.2 Microdeletion Syndrome Using Prequel® Prenatal Screen

16 Apr 2024 09:15:00 By Nasdaq GlobeNewswire

Myriad Genetics Research Shows Reduction in Hospitalizations for Patients with Depression after GeneSight Testing

09 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date

21 Mar 2024 21:40:00 By Nasdaq GlobeNewswire

Myriad Genetics Announces Patent Granted for SneakPeek® Snap Device

20 Mar 2024 16:05:00 By Nasdaq GlobeNewswire

Myriad Genetics Reports Strong Fourth Quarter and Full-Year 2023 Financial Results; Fourth Quarter Revenue of $197 Million and Full-Year Revenue of $753 Million Each Grew 11% Year-Over-Year; Delivered GAAP EPS of $(0.36) and Adjusted EPS of $0.04 in the Fourth Quarter 2023; Raising 2024 Revenue Guidance

27 Feb 2024 16:05:01 By Nasdaq GlobeNewswire

Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3

27 Feb 2024 09:15:00 By Nasdaq GlobeNewswire